Teva, Active Biotech halt higher doses of oral MS drug in trials
Advertisement
Jerusalem: Teva Pharmaceutical Industries and Active Biotech will discontinue higher doses of their oral drug in development for multiple sclerosis in two trials, citing the occurrence of non-fatal cardiovascular events in eight patients.
Both trials of laquinimod will continue with the lower dose of 0.6 mg daily where there were no issues.
Israel-based Teva and Sweden's Active Biotech said a monitoring committee had identified an imbalance in the number of cardiovascular events in patient trials using 1.2 mg and 1.5 mg daily doses.
"Teva is notifying trial sites to discontinue the higher doses immediately in both trials and will encourage participants to continue follow ups," it said in a statement on Monday.
Through a licensing agreement, Teva has global rights to develop and commercialise laquinimod, a small-molecule entity discovered by Active Biotech.
Both trials of laquinimod will continue with the lower dose of 0.6 mg daily where there were no issues.
Israel-based Teva and Sweden's Active Biotech said a monitoring committee had identified an imbalance in the number of cardiovascular events in patient trials using 1.2 mg and 1.5 mg daily doses.
"Teva is notifying trial sites to discontinue the higher doses immediately in both trials and will encourage participants to continue follow ups," it said in a statement on Monday.
Through a licensing agreement, Teva has global rights to develop and commercialise laquinimod, a small-molecule entity discovered by Active Biotech.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.